Receptor mediated tumor targeting: An emerging approach for cancer therapy

Current Drug Delivery

Volumn 8, Issue 1, 2011, Pages 45-58

  Mohanty, Chandana ^a   Das, Manasi ^a   Kanwar, Jagat R ^b   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

Ligand; Nanocarrier; Receptor; Tumor targeting

Indexed keywords

APTAMER; ARABINOGALACTAN; ARTEMISIN; ARTEMISINIC ACID; BEVACIZUMAB; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CETUXIMAB; CISPLATIN; CREMOPHOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR; IMMUNOLIPOSOME; INTEGRIN RECEPTOR; LECTIN RECEPTOR; LIPOSOME; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY VASCULOTROPIN C; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; THYMOPENTIN; TRANSFERRIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; YTTRIUM 90;

ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER THERAPY; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; ENDOCYTOSIS; HUMAN; ISOTOPE LABELING; MICELLE; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, PEPTIDE;

EID: 78650875977     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720111793663606     Document Type: Article

References (114)

1. Chen, J.; Wu, H.; Han, D.; Xie, C. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett., 2006, 231, 169-175.
2. Das, M.; Mohanty, C.; Sahoo, S.K. Ligand-based targeted therapy for cancer tissue. Expert Opin. Drug Deliv., 2009, 6, 285-304.
3. Sahoo, S.K.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today, 2003, 8, 1112-1120.
4. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54, 631-651.
5. Liu, Y.; Miyoshi, H.; Nakamura, M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer., 2007, 120, 2527-2537.
6. Torchilin, V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS. J., 2007, 9, 128-147.
7. Vasir, J.K.; Labhasetwar, V. Targeted drug delivery in cancer therapy. Technol. Cancer Res. Treat., 2005, 4, 363-374.
8. Sinha, R.; Kim, G.J.; Nie, S.; Shin, D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther., 2006, 5, 1909-1917.
9. Murphy, E.A.; Majeti, B.K.; Barnes, L.A.; Makale, M.; Weis, S.M.; Lutu-Fuga, K.; Wrasidlo, W.; Cheresh, D.A. Nanoparticlemediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl. Acad. Sci. USA, 2008, 105, 9343-9348.
10. Yotsumoto, F.; Sanui, A.; Fukami, T.; Shirota, K.; Horiuchi, S.; Tsujioka, H.; Yoshizato, T.; Kuroki, M.; Miyamoto, S. Efficacy of ligand-based targeting for the EGF system in cancer. Anticancer Res., 2009, 29, 4879-4885.
11. Utreja, P.; Jain, S.; Tiwary, A.K. Novel drug delivery systems for sustained and targeted delivery of anticancer drugs: current status and future prospects. Curr. Drug Deliv., 2010, 7(2), 152-61.
12. Alexis, F.; Pridgen, E.M.; Langer, R.; Farokhzad, O.C. Nanoparticle technologies for cancer therapy. Handb. Exp. Pharmacol., 2010, 197, 55-86.
13. Shaffer, C. Nanomedicine transforms drug delivery. Drug Discov. Today, 2005, 10, 1581-1582.
14. Acharya, S.; Dilnawaz, F.; Sahoo, S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials., 2009, 30, 5737-5750.
15. Malam, Y.; Loizidou, M.; Seifalian, A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci., 2009, 30, 592-599.
16. Dhar, S.; Gu, F.X.; Langer, R.; Farokhzad, O.C.; Lippard, S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA, 2008, 105, 17356-17361.
17. Huwyler, J.; Cerletti, A.; Fricker, G.; Eberle, A.N.; Drewe, J. Bypassing of P-glycoprotein using immunoliposomes. J. Drug Target., 2002, 10, 73-79.
18. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev. Drug Discov., 2005, 4, 145-160.
19. Kellen, J.A. The reversal of multidrug resistance: an update. J. Exp. Ther. Oncol., 2003, 3, 5-13.
20. Babincova, M.; Babinec, P. Magnetic drug delivery and targeting: principles and applications. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub., 2009, 153, 243-250.
21. Huynh, N.T.; Passirani, C.; Saulnier, P.; Benoit, J.P. Lipid nanocapsules: a new platform for nanomedicine. Int. J. Pharm., 2009, 379, 201-209.
22. Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Karydas, A.G.; Ithakissios, D.S. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control Release., 2002, 79, 123-135.
23. Parveen, S.; Sahoo, S.K. Polymeric nanoparticles for cancer therapy. J. Drug Target., 2008, 16, 108-123.
24. Eberle, A.N.; Mild, G. Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods. J. Recept. Signal Transduct. Res., 2009, 29, 1-37.
25. Mezo, G.; Manea, M. Receptor-mediated tumor targeting based on peptide hormones. Expert Opin. Drug Deliv., 2010, 7, 79-96.
26. Singh, R.; Lillard, J.W., Jr. Nanoparticle-based targeted drug delivery. Exp. Mo.l Pathol., 2009, 86, 215-223.
27. Brumlik, M.J.; Daniel, B.J.; Waehler, R.; Curiel, D.T.; Giles, F.J.; Curiel, T.J. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. Expert Opin. Drug Deliv., 2008, 5, 87-103.
28. Vasir, J.K.; Labhasetwar, V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev., 2007, 59, 718-728.
29. Pun, S.H.; Tack, F.; Bellocq, N.C.; Cheng, J.; Grubbs, B.H.; Jensen, G.S.; Davis, M.E.; Brewster, M.; Janicot, M.; Janssens, B.; Floren, W.; Bakker, A. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrinbased particles. Cancer Biol. Ther., 2004, 3, 641-650.
30. Anabousi, S.; Bakowsky, U.; Schneider, M.; Huwer, H.; Lehr, C.; Ehrhardt, C. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur. J. Pharm. Sci., 2006, 29, 367-374.
31. Vandewalle, B.; Granier, A.M.; Peyrat, J.P.; Bonneterre, J.; Lefebvre, J. Transferrin receptors in cultured breast cancer cells. J. Cancer Res. Clin. Oncol., 1985, 110, 71-76.
32. Li, X.; Dingb, L.; Xub, Y.; Wangb, Y.; Pinga, Q. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int. J. Pharma., 2009, 373, 116-123.
33. Sahoo, S.K.; Ma, W.; Labhasetwar, V. Efficacy of transferrinconjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer, 2004, 112, 335-340.
34. Hou, J.; Wang, D.; Zhang, R.; Wang, H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res., 2008, 14, 5519-5530.
35. Nam, W.; Tak, J.; Ryu, J.K.; Jung, M.; Yook, J.I.; Kim, H.J.; Cha, I.H. Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head Neck., 2007, 29, 335-340.
36. Nakase, I.; Lai, H.; Singh, N.P.; Sasaki, T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferring conjugation. Int. J. Pharm., 2008, 354, 28-33.
37. Li, J.L.; Liu, X.Y. Fabrication and biofunctionalization of seleniumpolypyrrole core-shell nanoparticles for targeting and imaging of cancer cells. J. Nanosci. Nanotechnol., 2008, 8, 2488-2491.
38. Cummings, J.; McArdle, C.S. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br. J. Cancer., 1986, 53, 835-8.
39. Shia, J.; Klimstra, D.S.; Nitzkorski, J.R.; Low, P.S.; Gonen, M.; Landmann, R.; Weiser, M.R.; Franklin, W.A.; Prendergast, F.G.; Murphy, L.; Tang, L.H.; Temple, L.; Guillem, J.G.; Wong, W.D.; Paty, P.B. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum. Pathol., 2008, 39, 498-505.
40. Sudimack, J.; Lee, R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev., 2000, 41, 147-162.
41. Leamon, C.P.; Reddy, J.A. Folate-targeted chemotherapy. Adv. Drug. Deliv. Rev., 2004, 56, 1127-1141.
42. Lu, Y.; Low, P.S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother., 2002, 51, 153-162.
43. Esmaeili, F.; Ghahremani, M.H.; Ostad, S.N.; Atyabi, F.; Seyedabadi, M.; Malekshahi, M.R.; Amini, M.; Dinarvand, R. Folatereceptortargeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Target., 2008, 16, 415-23.
44. Pan, J.; Feng, S.S. Targeted delivery of paclitaxel using folatedecorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials., 2008, 29, 2663-2672.
45. Pinhassi, R.I.; Assaraf, Y.G.; Farber, S.; Stark, M.; Ickowicz, D.; Drori, S.; Domb, A.J.; Livney, Y.D. Arabinogalactan-folic aciddrug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules, 2010, 11, 294-303.
46. Laskin, J.J.; Sandler, A.B. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat. Rev., 2004, 30, 1-17.
47. Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 1995, 19, 183-232.
48. Schwechheimer, K.; Huang, S.; Cavenee, W.K. EGFR gene amplification rearrangement in human glioblastomas. Int. J. Cancer., 1995, 62, 145-8.
49. Bohl Kullberg, E.; Bergstrand, N.; Carlsson, J.; Edwards, K.; Johnsson, M.; Sjoberg, S.; Gedda, L. Development of EGFconjugated liposomes for targeted delivery of boronated DNAbinding agents. Bioconjug. Chem., 2002, 13, 737-43.
50. Bohl Kullberg, E.; Carlsson, J.; Edwards, K.; Capala, J.; Sjoberg, S.; Gedda, L. Introductory experiments on ligand liposomes as delivery agents for boron neutron capture therapy. Int. J. Oncol., 2003, 23, 461-7.
51. Carlsson, J.; Kullberg, E.B.; Capala, J.; Sjoberg, S.; Edwards, K.; Gedda, L. Ligand liposomes and boron neutron capture therapy. J Neurooncol. 2003, 62, 47-59.
52. Kullberg, E.B.; Nestor, M.; Gedda, L. Tumor-cell targeted epiderimal growth factor liposomes loaded with boronated acridine: uptake and processing. Pharm. Res., 2003, 20, 229-36.
53. Lin, S.Y.; Makino, K.; Xia, W.; Matin, A.; Wen, Y.; Kwong, K.Y.; Bourguignon, L.; Hung, M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol., 2001, 3, 802-8.
54. Torrisi, M.R.; Lotti, L.V.; Belleudi, F.; Gradini, R.; Salcini, A.E.; Confalonieri, S.; Pelicci, P.G.; Di Fiore, P.P. Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization. Mol. Biol. Cell., 1999, 10, 417-34.
55. Wang, J.; Chen, P.; Su, Z.F.; Vallis, K.; Sandhu, J.; Cameron, R.; Hendler, A.; Reilly, R.M. Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. Nucl. Med. Biol., 2001, 28, 895-902.
56. Tseng, C.L.; Wu, S.Y.; Wang, W.H.; Peng, C.L.; Lin, F.H.; Lin, C.C.; Young, T.H.; Shieh, M.J. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials., 2008, 29, 3014-22.
57. Tseng, C.L.; Wang, T.W.; Dong, G.C.; Yueh-Hsiu Wu, S.; Young, T.H.; Shieh, M.J.; Lou, P.J.; Lin, F.H. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials., 2007, 28, 3996-4005.
58. Grunwald, V.; Hidalgo, M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst., 2003, 95, 851-67.
59. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol., 2003, 21, 2787-99.
60. Harries, M.; Smith, I. The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer., 2002, 9, 75-85.
61. Dilnawaz, F.; Singh, A.; Mohanty, C.; Sahoo, S.K. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials., 2010, 31, 3694-706.
62. Nobs, L.; Buchegger, F.; Gurny, R.; Allemann, E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug. Chem., 2006, 17, 139-45.
63. Li, C. Poly(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev., 2002, 54, 695-713.
64. Yin, Y.; Chen, D.; Qiao, M.; Wei, X.; Hu, H. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J. Control Release, 2007, 123, 27-38.
65. Gao, X.; Tao, W.; Lu, W.; Zhang, Q.; Zhang, Y.; Jiang, X.; Fu, S. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials., 2006, 27, 3482-3490.
66. Backer, M.V.; Gaynutdinov, T.I.; Patel, V.; Bandyopadhyaya, A.K.; Thirumamagal, B.T.; Tjarks, W.; Barth, R.F.; Claffey, K.; Backer, J.M. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol. Cancer Ther., 2005, 4, 1423-1429.
67. Kremer, C.; Breier, G.; Risau, W.; Plate, K.H. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res., 1997, 57, 3852-3859.
68. Plate, K.H.; Breier, G.; Weich, H.A.; Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature., 1992, 359, 845-848.
69. Shweiki, D.; Itin, A.; Soffer, D.; Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature., 1992, 359, 843-845.
70. Brown, L.F.; Berse, B.; Jackman, R.W.; Tognazzi, K.; Manseau, E.J.; Senger, D.R.; Dvorak, H.F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res., 1993, 53, 4727-4735.
71. Jain, R.K.; Safabakhsh, N.; Sckell, A.; Chen, Y.; Jiang, P.; Benjamin, L.; Yuan, F.; Keshet, E. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgendependent tumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA, 1998, 95, 10820-10825.
72. Cohen, T.; Gitay-Goren, H.; Sharon, R.; Shibuya, M.; Halaban, R.; Levi, B.Z.; Neufeld, G. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J. Biol. Chem., 1995, 270, 11322-11326.
73. Fiedler, W.; Graeven, U.; Ergun, S.; Verago, S.; Kilic, N.; Stockschlader, M.; Hossfeld, D.K. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 1997, 89, 1870-1875.
74. Liu, B.; Earl, H.M.; Baban, D.; Shoaibi, M.; Fabra, A.; Kerr, D.J.; Seymour, L.W. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem. Biophys. Res. Commun., 1995, 217, 721-727.
75. Pouget, J.P.; Mather, S.J. General aspects of the cellular response to low- and high-LET radiation. Eur. J. Nucl. Med., 2001, 28, 541-561.
76. Lu, J.; Jackson, J.K.; Gleave, M.E.; Burt, H.M. The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors. Cancer Chemother. Pharmacol., 2008, 61, 997-1005.
77. Wang, X.; Huang, D.Y.; Huong, S.M.; Huang, E.S. Integrin alphavbeta3 is a coreceptor for human cytomegalovirus. Nat. Med., 2005, 11, 515-521.
78. Wickham, T.J.; Mathias, P.; Cheresh, D.A.; Nemerow, G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell., 1993, 73, 309-319.
79. Brooks, P.C.; Montgomery, A.M.; Rosenfeld, M.; Reisfeld, R.A.; Hu, T.; Klier, G.; Cheresh, D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell., 1994, 79, 1157-1164.
80. Brooks, P.C.; Stromblad, S.; Klemke, R.; Visscher, D.; Sarkar, F.H.; Cheresh, D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest., 1995, 96, 1815-1822.
81. Schiffelers, R.M.; Koning, G.A.; ten Hagen, T.L.; Fens, M.H.; Schraa, A.J.; Janssen, A.P.; Kok, R.J.; Molema, G.; Storm, G. Antitumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control Release, 2003, 91, 115-122.
82. Schiffelers, R.M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P.Y.; Scaria, P.V.; Woodle, M.C. CancersiRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic. Acids Res., 2004, 32, e149.
83. Temming, K.; Schiffelers, R.M.; Molema, G.; Kok, R.J. RGDbased strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat., 2005, 8, 381-402.
84. Temming, K.; Meyer, D.L.; Zabinski, R.; Dijkers, E.C.; Poelstra, K.; Molema, G.; Kok, R.J. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjug. Chem., 2006, 17, 1385-1394.
85. Winter, P.M.; Caruthers, S.D.; Kassner, A.; Harris, T.D.; Chinen, L.K.; Allen, J.S.; Lacy, E.K.; Zhang, H.; Robertson, J.D.; Wickline, S.A.; Lanza, G.M. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res., 2003, 63, 5838-5843.
86. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998, 279, 377-380.
87. Wang, Z.; Chui, W.K.; Ho, P.C. Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of it physicochemical properties and anticancer activity to malignant cancer cells. Pharm. Res., 2009, 26, 1162-1171.
88. Xiong, X.B.; Mahmud, A.; Uludag, H.; Lavasanifar, A. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells. Pharm. Res., 2008, 25, 2555-2566.
89. Curnis, F.; Sacchi, A.; Gasparri, A.; Longhi, R.; Bachi, A.; Doglioni, C.; Bordignon, C.; Traversari, C.; Rizzardi, G.P.; Corti, A Isoaspartate- glycine-arginine: a new tumor vasculature-targeting motif. Cancer Res., 2008, 68, 7073-7082.
90. Dijkgraaf, I.; Rijnders, A.Y.; Soede, A.; Dechesne, A.C.; van Esse, G.W.; Brouwer, A.J.; Corstens, F.H.; Boerman, O.C.; Rijkers, D.T.; Liskamp, R.M. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org. Biomol. Chem., 2007, 5, 935-944.
91. Hood, J.D.; Bednarski, M.; Frausto, R.; Guccione, S.; Reisfeld, R.A.; Xiang, R.; Cheresh, D.A. Tumor regression by targeted gene delivery to the neovasculature. Science, 2002, 296, 2404-2407.
92. Hallahan, D.; Geng, L.; Qu, S.; Scarfone, C.; Giorgio, T.; Donnelly, E.; Gao, X.; Clanton, J. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell., 2003, 3, 63-74.
93. Went, P.; Vasei, M.; Bubendorf, L.; Terracciano, L.; Tornillo, L.; Riede, U.; Kononen, J.; Simon, R.; Sauter, G.; Baeuerle, P.A. Frequent high-level expression of the immunotherapeutic target EpCAM in colon, stomach, prostate and lung cancers. Br. J. Cancer., 2006, 94, 128-135.
94. Winkler, J.; Martin-Killias, P.; Pluckthun, A.; Zangemeister-Wittke, U. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol. Cancer Ther., 2009, 8, 2674-2683.
95. Hussain, S.; Pluckthun, A.; Allen, T.M.; Zangemeister-Wittke, U. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Mol. Cancer Ther., 2006, 5, 3170-3180.
96. Hussain, S.; Pluckthun, A.; Allen, T.M.; Zangemeister-Wittke, U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol. Cancer Ther., 2007, 6, 3019-3027.
97. Koyama, S.; Ebihara, T.; Fukao, K. Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. J. Cancer Res. Clin. Oncol., 1992, 118, 609-614.
98. Skelding, A.K.; Barry, D.R.; Shafren, D.R.;. Systemic targeting of metastasic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res., Treat., 2009., 113, 21-30.
99. Melis, M.; Spatafora, M.; Melodia, A.; Pace, E.; Gjomarkaj, M.; Merendino, A.M.; Bonsignore, G. ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells. Eur. Respir. J., 1996, 9, 1831-1838.
100. Yusuf-Makagiansar, H.; Yakovleva, T.V.; Tejo, B.A.; Jones, K.; Hu, Y.; Verkhivker, G.M.; Audus, K.L.; Siahaan, T.J. Sequence recognition of alpha-LFA-1-derived peptides by ICAM-1 cell receptors: inhibitors of T-cell adhesion. Chem. Biol. Drug Des., 2007, 70, 237-246.
101. Chittasupho, C.; Xie, S.X.; Baoum, A.; Yakovleva, T.; Siahaan, T.J.; Berkland, C.J. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur. J. Pharm. Sci., 2009, 37, 141-150.
102. Cho, K.; Wang, X.; Nie, S.; Chen, Z.G.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14, 1310-1316.
103. Farokhzad, O.C.; Cheng, J.; Teply, B.A.; Sherifi, I.; Jon, S.; Kantoff, P.W.; Richie, J.P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA, 2006, 103, 6315-6320.
104. Cheng, J.; Teply, B.A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F.X.; Levy-Nissenbaum, E.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials., 2007, 28, 869-876.
105. Pinto, J.T.; Suffoletto, B.P.; Berzin, T.M.; Qiao, C.H.; Lin, S.; Tong, W.P.; May, F.; Mukherjee, B.; Heston, W.D. Prostatespecific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res., 1996, 2, 1445-1451.
106. Hattori, Y.; Maitani, Y. Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther., 2005, 12, 796-809.
107. Hultdin, J.; Van Guelpen, B.; Bergh, A.; Hallmans, G.; Stattin, P. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int. J. Cancer., 2005, 113, 819-824.
108. Stern, S.T.; McNeil, S.E. Nanotechnology safety concerns revisited. Toxicol. Sci., 2008, 101, 4-21.
109. Oberdorster, E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ. Health Perspect., 2004, 112, 1058-1062.
110. DERFUS, A.; CHAN, W.; BHATIA, S. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett., 2004, 4, 11 -18.
111. Jaiswal, J.K.; Mattoussi, H.; Mauro, J.M.; Simon, S.M. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat. Biotechnol., 2003, 21, 47-51.
112. Ballou, B.; Lagerholm, B.C.; Ernst, L.A.; Bruchez, M.P.; Waggoner, A.S. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem., 2004, 15, 79-86.
113. Morishita, M.; Peppas, N.A. Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today., 2006, 11, 905-910.
114. Hamman, J.H.; Enslin, G.M.; Kotze, A.F. Oral delivery of peptide drugs: barriers and developments. Bio. Drugs, 2005, 19, 165-177.